Categories
Change Password!
Reset Password!
Tramadol/paracetamol combination improves pain control, functional ability, and sleep in grade I–II KOA patients.
A new study highlights the potential of a fixed-dose tramadol/paracetamol combination (75/650 mg) in managing early-stage knee osteoarthritis (KOA), offering meaningful pain relief and improved quality of life. The study led by Alessandro Conforti et al. included 30 people diagnosed with grade I–II KOA as per the Kellgren-Lawrence classification. Volunteers received a 15-day course of tramadol/paracetamol (75/650 mg). Pain levels were evaluated via the Numerical Rating Scale (NRS).
On the other hand, functional mobility and quality of sleep were examined with the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) and the Pittsburgh Sleep Quality Index (PSQI), respectively. Findings were promising: 86% of patients experienced at least 30% pain reduction, while 43% achieved a 50% reduction. Functional mobility and quality of sleep also boosted remarkably. Adverse effects, such as nausea, itching, and sleepiness, were reported in only 10% of patients and did not require discontinuation of therapy.
Importantly, the treatment’s potency was consistent across different demographic and clinical subgroups, indicating potential broad applicability. This retrospective observational study adds to evidence that tramadol/paracetamol is a valuable first-line therapy, helping patients manage pain, maintain mobility, and boost overall well-being.
Rheumatism
Evaluation of tramadol/paracetamol 75 mg/650 mg combination therapy for early-stage knee osteoarthritis: a retrospective observational study
Alessandro Conforti et al.
Comments (0)